SGT 501
Alternative Names: SGT-501Latest Information Update: 27 Jan 2025
At a glance
- Originator Solid Biosciences
- Class Antiarrhythmics; Gene therapies
- Mechanism of Action CASQ2 protein replacements; Gene transference; Ryanodine receptor calcium release channel replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Polymorphic catecholergic ventricular tachycardia
Most Recent Events
- 15 Jan 2025 Solid Biosicences plans to file an IND application for Polymorphic catecholergic ventricular tachycardia in first half of 2025
- 31 Dec 2024 SGT 501 receives Rare Pediatric Disease designation from the FDA for Polymorphic catecholergic ventricular tachycardia before December 2024
- 06 Nov 2024 Solid Biosciences completes a pre-IND meeting with the US FDA for SGT 501